Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger
Authors:
- 19 February 2018
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 20 (9) , 1168-1174
Abstract
The subgroup of young patients with non-small-cell lung cancer (NSCLC) is poorly understood. We retrospectively studied the clinical characteristics, gene mutations, and outcomes of patients with NSCLC (aged ≤ 40 years).Keywords
Funding Information
- The National Natural Science Foundation of China (No. 81572273, No. 81602015)
- Clinical Science and Technology Project of Jiangsu Province (No. BL2013026)
This publication has 23 references indexed in Scilit:
- First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE studyAnnals of Oncology, 2015
- Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United StatesFrontiers in Oncology, 2015
- Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer AuditQJM: An International Journal of Medicine, 2015
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California Cancer Registry analysisLung Cancer, 2014
- EGFR Mutation and Brain Metastasis in Pulmonary AdenocarcinomasJournal of Thoracic Oncology, 2014
- Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factorsBMC Cancer, 2012
- Multicenter analysis of lung cancer patients younger than 45 years in ShanghaiCancer, 2010
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine, 2010
- Distinctive Characteristics of Non-small Cell Lung Cancer (NSCLC) in the Young: A Surveillance, Epidemiology, and End Results (SEER) AnalysisJournal of Thoracic Oncology, 2010